Actelion (OTCMKTS:ALIOF) and Mannatech (NASDAQ:MTEX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.
Earnings and Valuation
This table compares Actelion and Mannatech’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Actelion||$2.46 billion||12.17||$707.04 million||N/A||N/A|
|Mannatech||$176.70 million||0.25||-$1.78 million||N/A||N/A|
Volatility and Risk
Actelion has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500.
Mannatech pays an annual dividend of $2.00 per share and has a dividend yield of 10.8%. Actelion does not pay a dividend.
This table compares Actelion and Mannatech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
24.1% of Mannatech shares are held by institutional investors. 24.7% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Actelion and Mannatech, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mannatech beats Actelion on 6 of the 10 factors compared between the two stocks.
Actelion Ltd. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of low molecular weight drugs. It specializes in the field of pulmonary arterial hypertension (PAH). It also specializes in human biology, especially in specific families of molecular targets, such as G-Protein Coupled Receptors. Its portfolio of PAH treatments covers the spectrum of disease, from World Health Organization (WHO) Functional Class (FC) II through to Functional Class (FC) IV, with oral, inhaled and intravenous medications. It also has treatments for a range of specialist diseases, including type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides type cutaneous T-cell lymphoma. Its products include Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Ventavis (iloprost), Veletri (epoprostenol for injection), Zavesca (miglustat) and Valchlor (mechlorethamine) gel.
Mannatech, Incorporated provides wellness solutions. The company develops, markets, and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. It markets its products through network marketing channels in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. The company was founded in 1993 and is headquartered in Coppell, Texas.
Receive News & Ratings for Actelion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actelion and related companies with MarketBeat.com's FREE daily email newsletter.